Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04225208 · ClinicalTrials.gov registry record · Phase 1

Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers

A Phase 1 study of Healthy Volunteers, sponsored by Dizal Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
8
Enrollment target
1
Study location

NCT04225208 is a Phase 1 study of Healthy Volunteers that has completed, run by Dizal Pharmaceuticals. The registered enrollment target is 8 participants, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04225208, a Phase 1 study of Healthy Volunteers, has completed, sponsored by Dizal Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

This is a phase I, open label, healthy volunteers, ADME study with single oral administration of \[14C\]-AZD4205.

Conditions Studied

Interventions

  • DRUG [14C]-AZD4205, single 50 mg oral dose administrated on day 1

Study Locations (1)

Maryland

  • Pharmaron CPC - Baltimore

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2020-01-06
Est. Completion 2020-03-02
Phase Phase 1

Sponsor

Dizal Pharmaceuticals

15 total trials

What the Registry Record Tells You About NCT04225208

The ClinicalTrials.gov registry entry for NCT04225208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 482-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (98% lower). The listed sponsor is Dizal Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy Volunteers appearing as the primary indexed condition, and to 1 intervention - of which [14C]-AZD4205, single 50 mg oral dose administrated on day 1 is the first listed.

NCT04225208 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.

Frequently Asked Questions

What is clinical trial NCT04225208 about?

NCT04225208 is a clinical study titled "Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers". This is a phase I, open label, healthy volunteers, ADME study with single oral administration of \[14C\]-AZD4205.

What is the current status of trial NCT04225208?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-01-06. Estimated completion is 2020-03-02.

What conditions does trial NCT04225208 study?

This clinical trial studies the following conditions: Healthy Volunteers.

What interventions are being tested in trial NCT04225208?

The interventions under investigation include: [14C]-AZD4205, single 50 mg oral dose administrated on day 1 (DRUG).

Who is sponsoring clinical trial NCT04225208?

This trial is sponsored by Dizal Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04225208 being conducted?

This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.